RT info:eu-repo/semantics/article T1 Systematic review and meta-analysis provide no guidance on management of asymptomatic bacteriuria within the first year after kidney transplantation A1 Medina Polo, José A1 Falkensammer, Eva A1 Köves, Béla A1 Kranz, Jennifer A1 Tandogdu, Zafer A1 Tapia Herrero, Ana María A1 Cai, Tommaso A1 Wagenlehner, Florian M. E. A1 Schneidewind, Laila A1 Bjerklund Johansen, Truls Erik K1 Antibiotics K1 Antibióticos K1 Urologic diseases K1 Urinario, Aparato - Enfermedades - Tratamiento K1 Urology K1 Nephrology K1 Kidneys - Diseases K1 Riñones - Enfermedades K1 Kidneys - Transplantation K1 Riñones - Trasplante K1 Urinary tract infections K1 Vías urinarias - Infecciones K1 Insuficiencia renal aguda K1 Acute renal failure K1 Meta-analysis K1 Systematic reviews (Medical research) K1 Medicina - Investigación K1 Public health K1 3213.16 Urología K1 3205.06 Nefrología K1 32 Ciencias Médicas K1 3212 Salud Publica AB (1) Background: Urinary tract infections (UTIs) are among the most frequent complications in kidney transplant (KT) recipients. Asymptomatic bacteriuria (ASB) may be a risk factor for UTIs and graft rejection. We aimed to evaluate available evidence regarding the benefit of screening and treatment of ASB within the first year after KT. (2) Evidence acquisition: A systematic literature search was conducted in MEDLINE, the Cochrane Library CENTRAL and Embase. Inclusion criteria were manuscripts in English addressing the management of ASB after KT. The PICO questions concerned Patients (adults receiving a KT), Intervention (screening, diagnosis and treatment of ASB), Control (screening and no antibiotic treatment) and Outcome (UTIs, sepsis, kidney failure and death). (3) Evidence synthesis: The systematic review identified 151 studies, and 16 full-text articles were evaluated. Seven were excluded because they did not evaluate the effect of treatment of ASB. There was no evidence for a higher incidence of lower UTIs, acute pyelonephritis, graft loss, or mortality in patients not treated with antibiotics for ASB. Analysis of comparative non-randomized and observational studies did not provide supplementary evidence to guide clinical recommendations. We believe this lack of evidence is due to confounding risk factors that are not being considered in the stratification of study patients. PB MDPI SN 2079-6382 YR 2024 FD 2024 LK https://uvadoc.uva.es/handle/10324/70300 UL https://uvadoc.uva.es/handle/10324/70300 LA eng NO Antibiotics, 2024, Vol. 13, Nº. 5, 442 NO Producción Científica DS UVaDOC RD 13-nov-2024